Survivin expression in ovarian carcinoma: Correlation with apoptotic markers and prognosis

Modern Pathology

Volumn 16, Issue 6, 2003, Pages 574-583

  Cohen, Cynthia ^a,b   Lohmann, Christina M ^a   Cotsonis, George ^a   Lawson, Diane ^a   Santoianni, Robert ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Immunohistochemistry; Inhibitor of apoptosis proteins (IAP); Ovarian carcinoma; Survivin

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; APOPTOSIS; CARCINOMA; CELL COUNT; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038457729     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000073868.31297.B0     Document Type: Article

References (84)

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
2. Altieri DC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999;79:1327-33.
3. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542-7.
4. Deveraux QL, Reed JC. LAP family proteins - suppressors of apoptosis. Genes Dev 1999;13:239-52.
5. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-59.
6. Reed JC. The survivin saga goes in vivo. J Clin Invest 2001;108:965-9.
7. Geske FJ, Gerschenson LE. The biology of apoptosis. Hum Pathol 2001;32:1029-38.
8. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA. Apoptosis: definition, mechanisms, and relevance to disease. Am J Med 1999;107:489-506.
9. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna W, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20.
10. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 2002;184:105-16.
11. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000;31:1080-5.
12. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int J Mol Med 2002;10:211-6.
13. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 2002;21:315-20.
14. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4.
15. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998;58:1808-12.
16. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma [letter]. Lancet 1998;351:882-3.
17. Survivin apoptosis [editorial]. Lab Invest 1999;79:1325.
18. Kanwar JR, Shen W-P, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001;93:1541-52.
19. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113:1076-81.
20. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 2001;98:635-40.
21. Grossman D, McNiff JM, Li F, Altieri DC. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 1999;79:1121-6.
22. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001;108:981-90.
23. Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001;158:1757-65.
24. Anderson MH, Pederson LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001;61:869-72.
25. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000;60:1815-7.
26. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999;3:500-9.
27. Rosai J, editor. Ackerman's surgical pathology. Vol. 2. 8th ed. St. Louis: Mosby; 1996. p. 1461-539.
28. Goel A, Abou-Ellela A, DeRose PB, Cohen C. The prognostic significance of proliferation in prostate cancer: an image cytometric quantitation of MIB-1. J Urol Pathol 1996;4:213-25.
29. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez II, Maestre J, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-4.
30. Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001;8:305-10.
31. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001;92:271-8.
32. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001;163:109-16.
33. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001;95:92-5.
34. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
35. Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells in human prostate over-express the antiapoptosis protein survivin. Prostate 2001;48:7-15.
36. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452-3.
37. Nakanishi K, Tominaga S, Hiroi S, Kawai T, Aida S, Kasamatsu H, et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch 2002;441:559-63.
38. Saitoh Y, Yaginuma Y, Ishikawa M. Analysis of bcl-2, bax and survivin genes in uterine cancer. Int J Oncol 1999;15:137-41.
39. Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol 2001;19:537-42.
40. Hattori M, Sakamoto H, Satoh K, Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001;169:155-64.
41. Chiodino C, Cesinaro AM, Ottani D, Fantini F, Giannetti A, Trentini GP, et al. Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 1999;113:415-8.
42. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002;59:1406-12.
43. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, Shroyer KR. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 2001;32:119-25.
44. Konno R, Yamakawa H, Utsunomiya H, Ito K, Sato S, Yajima A. Expression of survivin and bcl-2 in the normal human endometrium. Mol Hum Reprod 2000;6:529-34.
45. Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, et al. Survivin, bcl-2, bax, and bcl-x gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 2003;21:306-12.
46. Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T, et al. Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem 2001;47:1729-31.
47. Sharp JD, Hausladen DA, Maher MG, Wheeler MA, Altieri DC, Weiss RM. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci 2002;7:e36-41.
48. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and prognostic implications. Anticancer Res 2002;22:2377-84.
49. Lo Muzio L, Staibano S, Pannone G, Mignogna MD, Mariggio A, Salvatore G, et al. Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol 2001;70:249-54.
50. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000;19:617-23.
51. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, Stein H, Hopfner M, et al. Prognostic value of nuclear survivin expression in esophageal squamous cell carcinoma. Cancer Res 2003;88:115-9.
52. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002;20:1063-8.
53. Kappler M, Kohler T, Kampf C, Diestelkotter P, Wurl P, Schmitz M, et al. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 2001;95:360-3.
54. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002;11:33-40.
55. Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M, et al. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 2001;36:1785-91.
56. Lehner R, Lucia MS, Jarboe EA, Orlicky D, Shroyer AL, McGregor JA, et al. Immunohistochemical localization of the LAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem 2002;10:134-8.
57. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002;86:886-92.
58. Ikeguchi M, Kaibara N. Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. Int J Mol Med 2001;8:661-6.
59. Lohmann CM, League AA, Clark WS, Lawson D, DeRose PB, Cohen C. Bcl-2:bax and bcl-2:bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: correlation with prognosis. Cytometry 2000;42:61-6.
60. Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 1999;35:1214-9.
61. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-84.
62. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, et al. Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105:341-9.
63. Marx D, Binder C, Meden H, Lenthe T, Ziemek T, Hiddemann T, et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 1997;17:2233-40.
64. Henricksen R, Wilander E, Oberg K. Expression and prognostic significance of bcl-2 in ovarian tumours. Br J Cancer 1995;72:1324-9.
65. Baekelandt M, Holm R, Nesland JM, Trope CG, Kristensen GB. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer. J Clin Oncol 2000;18:3775-81.
66. Ben-Hur H, Gurevich P, Huszar M, Ben-Arie A, Berman V, Tendler Y, et al. Apoptosis and apoptosis-related proteins in the epithelium of human ovarian tumors: immunohistochemical and morphometric studies. Eur J Gynecol Oncol 1999;20:249-53.
67. Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H, et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2002;82:1446-52.
68. Yamasaki F, Tokunaga O, Sugimori H. Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol Oncol 1997;66:439-48.
69. Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000;156:409-17.
70. Wehrli BM, Krajewski S, Gascoyne RD, Reed JC, Gilks CB. Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-x expression in ovarian surface epithelial tumors. Int J Gynecol Pathol 1998;17:255-60.
71. S expression in normal and neoplastic ovarian tissues. Clin Cancer Res 1998;4:517-24.
72. Joseph B, Lewensohn R, Zhivotovsky B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann N Y Acad Sci 2000;926:204-16.
73. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000;91:1204-9.
74. cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 2000;97:13103-7.
75. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16:2986-99.
76. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000;60:2805-9.
77. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998;273:11177-82.
78. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001;91:2026-32.
79. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000;156:393-8.
80. Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG, et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999;264:781-8.
81. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000;275:9102-5.
82. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, et al. Generation of survivin-specific CD8 + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000;60:4845-9.
83. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613-22.
84. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-57.